Vasiliki Triantafyllia

Athens, ESYE31 11527, Greece

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.

Polyunsaturated fatty acid-derived lipid mediator patterns determine viral pneumonia severity and risk for critical COVID-19.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: June 01, 2026

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.

Autoantibodies are highly prevalent in non-SARS-CoV-2 respiratory infections and critical illness.

Journal: JCI insight

Published: July 13, 2022

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: May 16, 2022

Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Journal: The Journal of experimental medicine

Published: March 22, 2022

Protocol for influenza A virus infection of mice and viral load determination.

Protocol for influenza A virus infection of mice and viral load determination.

Journal: STAR protocols

Published: February 11, 2022

Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

Autoantibodies targeting cytokines and connective tissue disease autoantigens are common in acute non-SARS-CoV-2 infections.

Journal: Research square

Published: January 25, 2022

The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies.

The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodies.

Journal: Research square

Published: January 19, 2022

Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results.

Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results.

Journal: World journal of biological chemistry

Published: November 06, 2021

Severity of neonatal influenza infection is driven by type I interferon and oxidative stress.

Severity of neonatal influenza infection is driven by type I interferon and oxidative stress.

Journal: Mucosal immunology

Published: October 26, 2021

Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19.

Genetic regulation of OAS1 nonsense-mediated decay underlies association with risk of severe COVID-19.

Journal: medRxiv : the preprint server for health sciences

Published: July 20, 2021

TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma.

TFEB signaling attenuates NLRP3-driven inflammatory responses in severe asthma.

Journal: Allergy

Published: July 18, 2021

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Journal: Science immunology

Published: July 13, 2021

Showing 1-12 of 15

Last Updated: 09/26/2026